Cytokinetics reports Phase 3 success for Myqorzo but shares tumble as investors weigh market impact

At the European Society of Cardiology meeting, Cytokinetics presented Phase 3 data for Myqorzo in non‑obstructive hypertrophic cardiomyopathy, showing benefit in both forms of the disease and distinguishing it from Bristol Myers Squibb’s Camzyos.

The results were published in the New England Journal of Medicine and highlighted by analysts as a strong validation of the drug’s potential, yet the company’s stock fell sharply after the presentation.

Arrowhead Pharmaceuticals used the forum to stress its competitive edge, while a separate failed study from Alnylam added pressure on that firm’s heart‑failure program.

Investors are watching how the positive readout for Myqorzo translates into market share and pricing, as the sell‑off suggests caution despite the clinical win.